FDA re­jects Cy­to­ki­net­ic­s' heart fail­ure drug, but the biotech has a back­up

The FDA re­ject­ed Cy­to­ki­net­ics’ lead can­di­date for heart fail­ure, say­ing the com­pa­ny didn’t pro­vide enough ev­i­dence of the drug’s ef­fi­ca­cy.

Cy­to­ki­net­ics re­vealed Tues­day that it re­ceived a com­plete re­sponse let­ter from the FDA for ome­cam­tiv mecar­bil to treat heart fail­ure with re­duced ejec­tion frac­tion.

Ac­cord­ing to the com­pa­ny, the FDA de­ter­mined that the Phase III tri­al, GALAC­TIC-HF, was “not suf­fi­cient­ly per­sua­sive to es­tab­lish sub­stan­tial ev­i­dence of ef­fec­tive­ness for re­duc­ing the risk of heart fail­ure events and car­dio­vas­cu­lar death in adults with chron­ic heart fail­ure with re­duced ejec­tion frac­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER